Your browser is no longer supported. Please, upgrade your browser.
Heat Biologics, Inc.
Index- P/E- EPS (ttm)-1.38 Insider Own3.80% Shs Outstand24.20M Perf Week8.38%
Market Cap233.85M Forward P/E- EPS next Y-1.17 Insider Trans-2.82% Shs Float24.20M Perf Month27.51%
Income-27.30M PEG- EPS next Q-0.30 Inst Own12.30% Short Float9.66% Perf Quarter-16.63%
Sales2.60M P/S89.94 EPS this Y61.30% Inst Trans-6.43% Short Ratio2.35 Perf Half Y13.27%
Book/sh5.67 P/B1.30 EPS next Y4.90% ROA-23.90% Target Price- Perf Year42.26%
Cash/sh4.16 P/C1.77 EPS next 5Y- ROE-25.80% 52W Range4.90 - 30.10 Perf YTD37.50%
Dividend- P/FCF- EPS past 5Y60.90% ROI-22.40% 52W High-76.61% Beta0.27
Dividend %- Quick Ratio44.00 Sales past 5Y- Gross Margin- 52W Low43.69% ATR0.74
Employees39 Current Ratio44.00 Sales Q/Q-44.40% Oper. Margin- RSI (14)51.19 Volatility18.76% 8.43%
OptionableYes Debt/Eq0.00 EPS Q/Q59.50% Profit Margin- Rel Volume1.29 Prev Close7.37
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume994.59K Price7.04
Recom2.00 SMA204.54% SMA504.61% SMA200-7.17% Volume716,015 Change-4.47%
Mar-03-21Initiated Cantor Fitzgerald Overweight $22
Oct-14-20Initiated B. Riley Securities Buy $4
Jun-20-16Initiated ROTH Capital Buy
Jan-08-16Initiated Noble Financial Buy $16
May-26-15Initiated H.C. Wainwright Buy $13
Sep-18-13Initiated Aegis Capital Buy $36
Jun-04-21 09:00AM  
May-24-21 06:20AM  
May-20-21 07:30AM  
May-19-21 07:30AM  
May-10-21 07:30AM  
May-05-21 07:30AM  
Apr-26-21 03:16AM  
Apr-14-21 06:55AM  
Apr-12-21 07:30AM  
Mar-25-21 09:00AM  
Mar-08-21 06:30AM  
Feb-16-21 08:08AM  
Feb-12-21 03:00PM  
Feb-10-21 02:44PM  
Feb-09-21 04:22PM  
Jan-27-21 07:30AM  
Jan-26-21 01:53AM  
Jan-20-21 07:30AM  
Jan-19-21 07:30AM  
Jan-11-21 08:00AM  
Jan-08-21 04:00PM  
Dec-16-20 07:30AM  
Dec-10-20 08:00AM  
Nov-30-20 06:48AM  
Nov-09-20 07:00AM  
Oct-30-20 02:40PM  
Oct-28-20 09:33AM  
Oct-07-20 07:30AM  
Sep-16-20 06:37AM  
Sep-09-20 07:30AM  
Sep-02-20 07:30AM  
Aug-30-20 12:41PM  
Aug-26-20 10:00AM  
Aug-24-20 11:14AM  
Aug-13-20 01:54PM  
Aug-12-20 12:47PM  
Aug-11-20 11:27AM  
Aug-07-20 07:00AM  
Aug-05-20 07:30AM  
Aug-03-20 10:00AM  
Jul-30-20 09:07AM  
Jul-29-20 12:05PM  
Jul-27-20 06:30AM  
Jun-22-20 10:54AM  
Jun-20-20 09:49AM  
Jun-18-20 07:30AM  
Jun-08-20 07:30AM  
Jun-04-20 07:30AM  
Jun-01-20 06:15AM  
May-29-20 08:00AM  
May-28-20 11:34AM  
May-27-20 08:00AM  
May-18-20 07:45AM  
May-15-20 09:30AM  
May-14-20 08:00AM  
May-11-20 08:00AM  
Apr-29-20 08:37AM  
Apr-13-20 03:27PM  
Apr-09-20 03:45PM  
Apr-01-20 08:00AM  
Mar-30-20 08:30AM  
Mar-23-20 02:38PM  
Mar-17-20 02:35PM  
Mar-16-20 08:00AM  
Mar-11-20 09:23AM  
Mar-09-20 10:55AM  
Mar-06-20 01:52PM  
Mar-05-20 04:45PM  
Mar-04-20 03:10PM  
Mar-03-20 02:41PM  
Feb-28-20 02:15PM  
Feb-24-20 02:59PM  
Jan-21-20 04:05PM  
Jan-16-20 09:50AM  
Jan-15-20 02:33PM  
Dec-23-19 08:39AM  
Dec-16-19 07:00AM  
Nov-29-19 05:05AM  
Nov-20-19 08:00AM  
Nov-19-19 07:56AM  
Nov-18-19 08:00AM  
Nov-15-19 08:30AM  
Nov-11-19 07:00AM  
Heat Biologics, Inc., a biopharmaceutical company, engages in the development of immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer; and HS-130 that is in phase I clinical trial for the treatment of advanced solid tumors. Its preclinical stage products include PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25; TNFRSF25 modulators for various immunotherapy approaches; and COVID-19 vaccine. Heat Biologics, Inc. has collaboration with Waisman Biomanufacturing to manufacture COVID-19 Vaccine. The company was incorporated in 2008 and is headquartered in Morrisville, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PRENDERGAST JOHN K ADirectorMay 14Sale5.8735,000205,292203,272May 18 05:00 PM
Smith Edward B IIIDirectorNov 12Sale1.03103,304106,4030Nov 13 05:31 PM
Ostrander William L.VP Finance/Corp SecyAug 13Option Exercise0.5215,6258,12515,625Aug 14 06:01 PM